International journal of chronic obstructive pulmonary disease · 2019
Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial.
СтатьяРандомизированное исследованиеEquivalence TrialНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ramírez-Venegas Alejandra, Velázquez-Uncal Mónica, Aranda-Chávez Adrián, Guzmán-Bouilloud Nicolás Eduardo, Mayar-Maya María Eugenia, Pérez Lara-Albisua José Luis, Hernández-Zenteno Rafael de Jesus, Flores-Trujillo Fernando, Sansores Raúl H
Аннотация
INTRODUCTION: The efficacy of long-acting bronchodilators for COPD associated with biomass (BE-COPD) has not been properly evaluated.
OBJECTIVE: To determine the acute effect of indacaterol (IND) 150 μg q.d and tiotropium (TIO) 18 μg q.d. on lung hyperinflation, walking distance (WD) and dyspnea during the six-minute walking test (6MWT) in moderate BE-COPD at 30, 60 and 240 mins post-drug administration.
DESIGN: Randomized, controlled, open-level, crossover noninferiority clinical trial. Forty-two women with BE-COPD were randomly assigned to a bronchodilator sequence: IND-TIO or vice versa.
RESULTS: There were statistically significant changes over time in inspiratory capacity (IC) (p<0.0001), FEV1 (p<0.0001) and FVC (p<0.0001) when IND was used. When TIO was administered, an increase over all time periods was observed only for FEV1 (p<0.0001) and FVC (p<0.0001), whereas for IC an increase was observed only at 30 mins and 24 hrs after TIO administration. We did not find clinically significant increases in WD and dyspnea after the administration of both bronchodilators.
CONCLUSION: Both IND and TIO showed significant and fast onset improvement in hyperinflation. Therefore, either of them may be recommended as a first line of treatment for COPD associated with BE-COPD.
OBJECTIVE: To determine the acute effect of indacaterol (IND) 150 μg q.d and tiotropium (TIO) 18 μg q.d. on lung hyperinflation, walking distance (WD) and dyspnea during the six-minute walking test (6MWT) in moderate BE-COPD at 30, 60 and 240 mins post-drug administration.
DESIGN: Randomized, controlled, open-level, crossover noninferiority clinical trial. Forty-two women with BE-COPD were randomly assigned to a bronchodilator sequence: IND-TIO or vice versa.
RESULTS: There were statistically significant changes over time in inspiratory capacity (IC) (p<0.0001), FEV1 (p<0.0001) and FVC (p<0.0001) when IND was used. When TIO was administered, an increase over all time periods was observed only for FEV1 (p<0.0001) and FVC (p<0.0001), whereas for IC an increase was observed only at 30 mins and 24 hrs after TIO administration. We did not find clinically significant increases in WD and dyspnea after the administration of both bronchodilators.
CONCLUSION: Both IND and TIO showed significant and fast onset improvement in hyperinflation. Therefore, either of them may be recommended as a first line of treatment for COPD associated with BE-COPD.
Предметные рубрики MeSH
Administration, InhalationAgedAged, 80 and overBiomassBronchodilator AgentsCross-Over StudiesEnvironmental ExposureExercise TestFemaleForced Expiratory VolumeHumansIndansInspiratory CapacityMiddle AgedPulmonary Disease, Chronic ObstructiveQuinolonesSmokeSpirometryTiotropium BromideTreatment OutcomeVital Capacity